Last reviewed · How we verify
Adjuvant chemotherapy
Adjuvant chemotherapy is a Chemotherapy regimen (multi-agent or single-agent cytotoxic) Small molecule drug developed by Institut de Cancérologie de Lorraine. It is currently FDA-approved for Adjuvant treatment of various solid tumors (breast cancer, colorectal cancer, gastric cancer, ovarian cancer, and others depending on regimen), Post-operative or post-radiation therapy to reduce recurrence risk. Also known as: XEOLX*6 courses, Carboplatin, Paclitaxel, mFOLFOX6.
Adjuvant chemotherapy uses cytotoxic drugs administered after primary cancer treatment to eliminate residual cancer cells and reduce recurrence risk.
Adjuvant chemotherapy uses cytotoxic drugs administered after primary cancer treatment to eliminate residual cancer cells and reduce recurrence risk. Used for Adjuvant treatment of various solid tumors (breast cancer, colorectal cancer, gastric cancer, ovarian cancer, and others depending on regimen), Post-operative or post-radiation therapy to reduce recurrence risk.
At a glance
| Generic name | Adjuvant chemotherapy |
|---|---|
| Also known as | XEOLX*6 courses, Carboplatin, Paclitaxel, mFOLFOX6, according to local/ national guidelines |
| Sponsor | Institut de Cancérologie de Lorraine |
| Drug class | Chemotherapy regimen (multi-agent or single-agent cytotoxic) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Adjuvant chemotherapy is a treatment strategy rather than a single drug, involving the use of chemotherapeutic agents (such as alkylating agents, antimetabolites, or topoisomerase inhibitors) given after surgery or radiation to target micrometastatic disease. The goal is to improve overall survival and disease-free survival by destroying cancer cells that may have escaped the primary tumor but are not yet clinically detectable.
Approved indications
- Adjuvant treatment of various solid tumors (breast cancer, colorectal cancer, gastric cancer, ovarian cancer, and others depending on regimen)
- Post-operative or post-radiation therapy to reduce recurrence risk
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Mucositis
- Fatigue
- Diarrhea
- Cardiotoxicity
- Secondary malignancy
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- Procedural Framing and Epidural Steroid Injection Outcomes (NA)
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjuvant chemotherapy CI brief — competitive landscape report
- Adjuvant chemotherapy updates RSS · CI watch RSS
- Institut de Cancérologie de Lorraine portfolio CI
Frequently asked questions about Adjuvant chemotherapy
What is Adjuvant chemotherapy?
How does Adjuvant chemotherapy work?
What is Adjuvant chemotherapy used for?
Who makes Adjuvant chemotherapy?
Is Adjuvant chemotherapy also known as anything else?
What drug class is Adjuvant chemotherapy in?
What development phase is Adjuvant chemotherapy in?
What are the side effects of Adjuvant chemotherapy?
Related
- Drug class: All Chemotherapy regimen (multi-agent or single-agent cytotoxic) drugs
- Manufacturer: Institut de Cancérologie de Lorraine — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment of various solid tumors (breast cancer, colorectal cancer, gastric cancer, ovarian cancer, and others depending on regimen)
- Indication: Drugs for Post-operative or post-radiation therapy to reduce recurrence risk
- Also known as: XEOLX*6 courses, Carboplatin, Paclitaxel, mFOLFOX6, according to local/ national guidelines
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing